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Abstract 
Despite tremendous advances in cancer treatment and survival rates, pancreatic cancer re-
mains one of the most deadly afflictions and the fourth leading cause of cancer deaths in the 
world. Matrix Metalloproteinases (MMPs) are thought to be involved in cancer progression. 
Matrix metalloproteinase (MMP)-2 is known to play a pivotal role in tumor invasion, metas-
tasis and angiogenesis, and validated to be the anticancer target. Inhibition of MMP-2 activity is 
able to reduce the cancer cell invasion and suppress tumor growth in vivo. Two novel pep-
tides, M204C4 and M205C4, which could specially inhibit MMP-2 activity, were identified by a 
phage display library screening. We showed that M204C4 and M205C4 inhibited the activity 
of MMP-2 in a dose dependent manner in vitro. Two peptides reduced MMP-2 mediated 
invasion of the pancreatic cancer cell lines PANC-1 and CFPAC-1, but not affected the ex-
pression and release of MMP-2. Furthermore, these two peptides could suppress tumor 
growth in vivo. Our results indicated that two peptides selected by phase display technology 
may be used as anticancer drugs in the future. 
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INTRODUCTION 
For most tumors, intravasation can be facilitated 
by molecular changes that promote the ability of car-
cinoma cells to cross the pericyte and endothelial cell 
barriers that form the walls of microvessels. Matrix 
metalloproteinases (MMPs), as a family of endopep-
tidases, play a major role in such processes, in which 
the extracellular matrix degradation related to cancer 
cell invasion, metastasis and angiogenesis is induced. 
According to the specificity and structure of MMPs 
substrates, all members of the MMP gene family can 
be classified into subgroups of collagenases, strome-
lysins, gelatinases, membrane-type MMPs, and other 
MMPs  (1).  The  two  MMPs  most  closely  correlated 
with  metastatic  potential  are  the  72kDa  MMP-2 
(gelatinase A) and the 92kDa MMP-9 (gelatinase B). 
They are secreted as zymogen and then cleaved into 
their active form (2). Experiments with mice lacking 
MMP-2 suggest that MMP-2 plays an important role 
in  human  cancers.  First,  the  number  of  metastasis 
colonies in the lung of MMP-2 knockout mice in ex-
perimental metastasis decreased significantly after i.v. 
injection of Lewis lung carcinoma or melanoma cells 
(3). Furthermore, the angiogenesis and growth of tu-
mors  were  reduced  in  MMP-2-deficient  mice  com-
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pared with wildtype mice (4). Deficiency in MMP-2 
resulted in suppression of tumor-induced angiogene-
sis in a dorsal air sac assay and reduction of support 
of  glioma  angioarchitecture  (5).  The  importance  of 
stromal MMP-2 in neovascularization was also con-
firmed in different angiogenic models, including aor-
tic  ring  assay,  retinal  angiogenesis,  and  choroidal 
neovascularization  (4,  6-7).  Additional  works  had 
shown  that  MMP-2  expression  was  correlated  with 
tumor metastasis in various cancers, especially pan-
creatic cancer and other aggressive malignant tumors 
(8-10). And the increased capacity of MMP-2 to syn-
ergistically promote tumor cell intravasation was tied 
to their ability to stimulate neoangiogenesis and the 
formation of leaky blood vessels. Hence, it suggested 
that MMP-2 played an important role in human can-
cers and was a prominent predictor of poor prognosis. 
In recent years, numerous MMP inhibitors have 
been  tested  in  different  clinical  trials,  especially 
MMP-2 inhibitors. In view of MMP-2 involvement in 
various  diseases,  inhibition  of  specific MMPs 
up-regulation may improve clinical symptoms of pa-
tients  (11-12).  However,  these  molecules  displayed 
serious side effects and only a few were allowed to 
attend  phase  III  clinical  trials.  In  addition,  Matrix 
metalloproteinases (MMPs) mediated the homeostasis 
of  the  extracellular  environment  (12).  It  was  unrec-
ommendable  to  suppress  the  expression  of  MMPs 
blindly. These reasons might partially account for the 
failure of MMP inhibitors in clinical trials. Until now, 
specific inhibitors of gelatinases have not been avail-
able  in  clinic.  Recently,  synthetic  peptide  inhibitors 
based on MMPs structure have been thought as a hot 
spot  of  study  on  specific  inhibitors.The  MMPs  are 
initially  synthesized  as  inactive  zymogens  with 
pro-peptide  which  must  be  removed  from 
pro-peptide domain before the enzyme is active (13). 
Therefore,  peptide  drugs  can  inhibit  extracellular 
MMPs activation directly, but not affected MMPs in-
tracellular expression. And peptide research on drug 
design  and  discovery  is  one  of  the  most  promising 
fields in the development of new drugs. Compared to 
small molecule compounds, peptide drugs offer vari-
ous advantages, such as high specificity and low tox-
icity. 
In  the  present  study,  we  use  phage  display 
technology for the high-throughput screening of pro-
tein–peptide  to  select  specific  inhibitors  of  MMP-2, 
and  then  obtain  two  novel  peptides  that  inhibit 
MMP-2 activity and suppress MMP-2 mediated pan-
creatic cancer cell invasion in vitro, and attenuated the 
growth of solid tumor in nude mice. These data indi-
cate that peptides selected from phage display library 
have potential effects as anticancer agents. 
EXPERIMENTAL PROCEDURES 
Materials 
Recombinant human MMP-2 enzyme was pur-
chased from RD company, USA. Ph.D.-12TM phage 
display  peptide  library  kit  containing  E.  coli  host 
strain ER2738 was purchased from New England Bi-
oLabs,  UK.  MMP-2  fluorimetric  drug  discovery  kit 
was  purchased  from  Biomol,  USA.  The  antibody 
against MMP-2 and anti-CD31/PECAM-1 were pur-
chased  from  Cell  Signal  Technology,  USA.  QCMTM 
24-well  cell  invasion  assay  kit  was  purchased  from 
Chemicon,  USA.  Dulbecco’s  modified  Eagle  media 
(DMEM)  and  fetal  bovine  serum  (FBS)  were  pur-
chased from Gibco, USA. PGE2 was purchased from 
Sigma-Aldrich Chemical, USA. 
Screening phage display library against MMP-2 
MMP-2 was immobilized  on the NUNC wells. 
The  MMP-2-coated  well  was  blocked  with  0.5% 
BSA/NaHCO3 for 2 hours at room temperature. For 
selection,  phages  (1.51015  pfu/ml)  from  the  linear 
12-amino acid random peptide phage display library 
diluted  in  0.1%BSA/  NaHCO3  were  added  into 
MMP-2-coated wells and incubated overnight at 4C. 
After  extensive  washing  with  TBST 
(TBS+0.1%(v/v)Tween-20),  the  bound  phages  were 
eluted with a low pH buffer (0.2M glycine-HCl, pH 
2.2). Recovered phages were amplified using compe-
tent Escherichia coli cells and then subjected to two 
subsequent  rounds  of  selection  on  MMP-2-coated 
wells. Phage binding was quantified by counting the 
phage titer in eluted aliquots as protocol described. 
Phages from selected clones were sequenced at Invi-
trogen Life Technologies (Shanghai, China). Peptide 
sequences were determined according to the inserted 
sequence in the phage genome. Peptides used in our 
assays  were  synthesized  in  the  Huachen  Limited 
company (Xian province, China). 
Fluorescent MMP-2 activity assay 
Protease  activity  of  MMP-2  was  measured  by 
using a self-quenching fluorogenic peptide substrate 
(Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)  as  previ-
ously referenced (14). Mca fluorescence is quenched 
by  the  Dpa  group  until  cleavage  by  MMPs  at  the 
Gly-Leu bond separates the two moieties. The assays 
are  performed  in  a  convenient  96-well  microplate 
format.  The  kit  is  useful  to  screen  inhibitors  of 
MMP-2, a potential therapeutic target. The compound 
NNGH(i) is also included as a prototypic control in-
hibitor.  To  analyze  inhibition,  MMP-2  was 
pre-incubated with selected phage clones or a range of 
concentrations of synthesized peptide for 45 minutes Int. J. Biol. Sci. 2012, 8 
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at 37C in reaction buffer to allow inhibitor/enzyme 
interaction, and then the substrate was added. Finally, 
enzymatic  activity  was  determined  by  continuous 
monitoring with a fluorescence spectrophotometer at 
excitation and emission wavelengths of 328 nm and 
393 nm, respectively. Drug concentrations inhibiting 
MMP-2  activity  by  50%  (IC50)  was  calculated  from 
relative reactive curve using the median-effect prin-
ciple. 
Cell culture 
Human pancreatic cancer cell lines, PANC-1 and 
CFPAC-1  were  obtained  from  the  American  Type 
Culture  Collection  (Manassas,  VA).  Cells  were  cul-
tured in DMEM containing 100 g/ml penicillin, 100 
g/ml streptomycin in the presence of 10% fetal bo-
vine serum (FBS) at 37C in a humidified CO2 incu-
bator and subcultured every 2-3 days. For the exper-
iments  described  below,  cells  were  trypsinized  and 
harvested on reaching 80% to 90% confluency. 
Zymography  
Zymography  was  performed  as  described  pre-
viously (15). Cells (1105) were seeded onto wells of 
24-well plates and allowed to adhere in the presence 
of serum. Media subsequently were replaced by 0.5 
ml of serum-free medium per well containing PGE2 or 
not.  After  24  hours  of  incubation,  the  conditioned 
media were collected. After collection, the media were 
spun at 800  g for 3 min at 4C to remove cell debris. 
The  supernatant  was  frozen  at  -20C  for  later  zy-
mography. Zymography was carried out as described 
previously. In brief, 25L of the conditioned medium 
for  each  sample  was  subjected  to  10%  SDS/PAGE 
1mg/mL  gelatin  incorporated  into  the  gel  mixture. 
Following the electrophoresis, the gels were soaked in 
2.5% triton X100 for 40 minutes, to remove SDS, and 
transferred  to  a  bath  containing  50mmol/L  Tris 
(pH8.0), 5 mmol/L CaCl2, and 2mol/L ZnCl2 at 37C 
for  20  hours.  The  gel  then  was  stained  with  0.1% 
coomassie blue in 45% methanol and 10% acetic acid. 
Experiments were repeated three times. 
Cell invasion assay 
Invasion of pancreatic cancer cells in vitro was 
measured  by  the  invasion  of  cells  through  Mat-
rigel-coated  trans-well  inserts  as  protocol  described 
(16). Briefly, thaw gel overnight at 2-8 °C before use, 
which was diluted up to two-fold with DMEM con-
taining different concentrations of peptides onto the 
Matrigel-coated inserts, and in the lower wells DMEM 
with 5% FBS was added as the chemoattractant. After 
48h  incubation  with  PGE2,  the  noninvasive  cells  on 
the  upper  surface  of  the  membrane  were  removed 
with a cotton swab. Cells that solubilized the Matrigel, 
passed through the 8 μm pores of the transwell, and 
attached to the lower surface of membrane were fixed 
with  10%  formaldehyde,  stained  with  0.1%  crystal 
violet solution, and photographed. For quantification, 
the transwell membranes were detached and solubil-
ized in 10% acetic acid solution (90% deionized water 
and 10% glacial acetic acid), and the intensity of the 
colored solution was quantified by spectrophotomet-
rical analysis at 590 nm. The intensity of the untreated 
control transwell was set to 100%. Each experiment 
performed with two replicate transwells was repeated 
three times independently. 
Animal Models  
Cell suspension of PANC-1 or CFPAC-1 human 
pancreatic cancer cells was prepared (108 cells/ml). A 
total of 0.1 ml of the cell suspension was injected (s.c.) 
into  the  right  upper  flank  of  6~8-week-old  female 
nude BALB/c mice (20~22g, n=6). When tumors mass 
was established (~50 mm in diameter), each 100µl of 
PBS containing synthetic peptides (100µM, 100ul each 
injection) was injected (s.c.) into tumor-surrounding 
tissues  of  a  nude  mouse  once  a  week  for  4  weeks. 
Tumor measurements and animal behavior observa-
tions were recorded daily. The short (r) and long (l) 
diameters of the tumors were measured and the tu-
mor volume of each was calculated as (r2× 1)/2. 30 
days after the treatment, all mice were sacrificed and 
then  the  size  and  weight  of  tumors  were  recorded. 
Inhibitive rate of tumor was calculated by using the 
formula:  inhibitive  rate  of  tumor  (%)  =  (1-  average 
tumor weight in treated group/average tumor weight 
in control) × 100%. Tumor volume and weight were 
presented as the mean ±SD. Animal studies were car-
ried out according to the Guidelines for Animal Ex-
periments  drawn  up  by  the  Committee  for  Animal 
Experiments of the National Cancer Center. 
Immunohistochemistry 
Subcutaneous  tumors  in  all  groups  were  har-
vested  and  processed  for  immunostaining  as  previ-
ously described (17). Tumors that had been frozen in 
OCT were sectioned in 8-μm slices, mounted on posi-
tively charged slides, and air-dried for 30 min. Tissue 
sections were then fixed in cold acetone followed by 
1:1 acetone/chloroform and acetone and then washed 
with  PBS.  Specimens  were  then  incubated  with  3% 
H2O2in  methanol  at  room  temperature  to  block  en-
dogenous  peroxidase.  After  12min,  these  sections 
were washed three times with PBS (pH 7.5), and in-
cubated  for  20  min  at  room  temperature  in  a  pro-
tein-blocking  solution  consisting  of  PBS  supple-
mented  with  1%  serum.  Anti-CD31/PECAM-1  rat Int. J. Biol. Sci. 2012, 8 
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monoclonal  antibody,  which  recognizes  plate-
let–endothelial  cell  adhesion  molecule-1  (PECAM-1) 
on  endothelial  cells,  and  anti-MMP-2 rabbit  mono-
clonal antibody were diluted 1:800 in protein-blocking 
solution and applied to the sections, which were in-
cubated  overnight  at  4°C.  Negative  controls  were 
stained with nonspecific immunoglobulin G (IgG) and 
the  appropriate  horseradish  peroxidase-conjugated 
secondary  antibody  was  used.  All  sections  were 
counterstained  with  Gill's  hematoxylin.  The  im-
munostained tumor sections were examined by bright 
field microscopy. 
Microvascular  density  (MVD)  was  assessed  by 
immunohistochemical analysis with antibodies to the 
endothelial marker CD31 and determined according 
to the  method (18). Briefly, the immunostained sec-
tions  were  initially  screened  at  low  magnifications 
(40× and 100×) to identify hot spots, which are the 
areas  of  highest  neovascularization.  Any  brown 
stained endothelial cell or endothelial cell cluster that 
was  clearly  separated  from  adjacent  microvessels, 
tumor cells, and other connective tissue elements was 
considered as a single, countable microvessel. Within 
the  hot  spot  area,  the  stained  microvessels  were 
counted in a single high-power (200×) field, and the 
average vessel count in 3 hot spots was considered as 
the  value  of  MVD.  All  counts  were  performed  by 
three investigators in a blinded manner. Microvessel 
counts  were  compared  between  the  observers  and 
discrepant  results  were  reassessed.  The  consensus 
was used as the final score for analysis. Cell prolifer-
ation was determined by using anti-PCNA immuno-
assaying.  The  nuclei  resulting  in  brown  staining  as 
PCNA-positive  indicated  proliferative  nuclei.  The 
number of cells was counted in three random fields 
from three different slides at 200× magnification. An 
average for the percentage of PCNA-positive cells was 
taken over these fields. The sections were observed by 
two pathologists in a blinded manner. 
Pharmacokinetic    
Before  animal  experiments,  the  8~10-week-old 
female ICR mice (24~26g) were fasted overnight. Two 
peptides in PBS were administrated through tail vein 
injection (20mg/kg, n=6). Animals were sacrificed at 
different time points (from 0.2 min to 30min). Blood 
was  centrifuged  (3000rpm,  5min,  4°C)  and  plasma 
was collected. The amount of peptides in plasma was 
quantified by UPLC-DAD-MS as references described 
(19-21). 
Chromatographic Conditions and Instrumen-
tation 
Ultra-performance  liquid  chromatography– 
tandem mass spectrometry. Analysis was performed 
on  the  ACQUITY  UPLC  H-Class  System  (Waters, 
Milford, MA), which consists of a quaternary pump 
solvent management system, an online degasser, an 
autosampler,  and  an  Acquity  photodiode  array  de-
tector.  An Acquity  UPLC  BEH  (50mm ×2.1mm,  1.7 
μm)  column  was  applied  for all  analyses.  The  raw 
data were acquired and processed with MassLynx 4.1 
software. The mobile phase was composed of A ((0.1% 
formic acid in Acetonitrile, v/v) and B (0.1% formic 
acid in H2O, v/v) with a gradient elution: 0-0.2min, 
5%A; 0.2-1min, 5-100% A; 1-4 min, 100% A; 4-5 min, 
100-5% A; 5-8 min, 5% A. The flow rate of the mobile 
phase was 0.3ml/min, and the column temperature 
was  maintained  at  30°C. Detection  wavelength  was 
set at 218nm for peptides. MS analysis was performed 
on  a  TQD  mass  spectrometer  connected  to  the  Ac-
quity UPLC instrument via an electrospray ionization 
interface (ESI). High-purity nitrogen was used as the 
nebulizer and auxiliary gas; argon was utilized as the 
collision gas. The TQD mass spectrometer was oper-
ated in positive ion mode with a capillary voltage of 
3.9kV,  a  sampling  cone  voltage  of  81V,  a  extractor 
voltage of 3V, a RFLens voltage of 0.1V, a desolvation 
temperature of 250 °C, a source temperature of 150°C, 
a collision energy of 6 V, and the mass range was set 
from m/z 400 to 2000. 
Statistical analysis 
Differences between groups were analyzed us-
ing two-sided t test and ANOVA with P < 0.05 con-
sidered statistically significant.  
RESULTS 
Identification of Peptide Sequences That Bind 
to Recombinant Human MMP-2 Enzyme 
In this study, the phage display technique was 
used  to  identify  peptide  sequences  that  bound  to 
MMP-2. A random 12-mer peptide phage display li-
brary composed of 2.7109 independent peptide se-
quences  was  screened  for  binding  to  immobilized 
recombinant  human  MMP-2  enzyme.  In  the  experi-
ment, the MMP-2-bound phages were recovered by 
elution with acidic buffer (0.2M glycine-HCl, pH2.2). 
A marked relative enrichment in the MMP-2-binding 
phage was detected, and bovine serum albumin (BSA) 
was used as a control target protein without enrich-
ment after three round biopannings (data not shown). 
Selected Phages on MMP-2 Enzyme Activity in 
vitro 
At the end of the biopanning, a total of 22 clones 
were  isolated.  DNA  from  these  phages  was  se-Int. J. Biol. Sci. 2012, 8 
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quenced,  and  the  predicted  12-mer  peptides  were 
aligned  (Fig.1).  To  further  determine  the  effects  of 
selected phage clones on the MMP-2 activity, the se-
lected phage clones were amplified, and the titer was 
detected  via  blue/white  plaque  assay.  The  20l  of 
selected  phages  at  the  concentration  of  5.01012 
pfu/ml, were added to the reaction solution as pro-
cedure described above, respectively. All clones could 
inhibit the activity of MMP-2 enzyme with different 
effects (Fig.1). To further determine peptide potency, 
M201  to  M219  were  identified  for  the  following 
screening. 
Synthetic Peptides inhibit MMP-2 Enzyme Ac-
tivity in vitro 
19 linear peptides binding to MMP-2 were syn-
thesized. The inhibiting effects of these peptides were 
analyzed in fluorescent MMP-2 activity assay. It was 
disappointed  that  the  expected  effect  was  not  ob-
served from all identified peptides. In order to con-
serve the original right conformation displayed on the 
phage surface according to the protocol suggestion, 
all polypeptides containing GGGS at the C-terminal 
end were synthesized respectively. Finally, M204C4 
and  M205C4  efficiently  inhibited  MMP-2-mediated 
self-quenching  fluorogenic  peptide  substrate  degra-
dation  in  a  dose-dependent  manner  (Fig.2)  with  a 
median effective inhibiting concentration (IC50) of 78.0 
and 38.8 nM. Therefore, M204C4 and M205C4 (shown 
in Table 1) were chosen as drug candidates for our 
studies. 
Table 1. Characterization of peptide candidates, M204C4 
and M205C4. 
  Sequence  Mol Wt  Purity 
M204C4 HWWQWPSSLQLRGGGS  1881.06  >95% 
M205C4 HNWTRWLLHPDRGGGS  1889.68  >95% 
 
 
 
 
Fig.1 Effects of different phage clones on the MMP-2 activity. The MMP-2 Fluorescent Assay was used to measure protease 
activity of MMP-2 with a quenched fluorescent peptide. Measure fluorescence at Ex/Em = 328/393 nm in a micro-plate reader.C: control; 
I: MMP-2 inhibitor NNGH; M201-M219: phage clones which have different peptide sequences. Black: different phage clones which have the 
same sequence. Values are the means±SD (n=3) of three individual experiments. Int. J. Biol. Sci. 2012, 8 
 
http://www.biolsci.org 
655 
 
Fig.2 M204C4 and M205C4 inhibit MMP-2 Enzyme Activity in vitro. To evaluate the effect of M204C4 and M205C4 on MMP-2 
Enzyme Activity, the MMP-2 Fluorescent Assay was used. After recombinant human MMP-2 was incubated with the indicated concen-
trations of peptides for 45 minutes at 37°C, and then the substrate was added. The plates were read continuously in a fluorescence 
microplate reader (Molecular Devices) over 30 min, at Ex/Em = 328/393. Values are the means±SD (n=3) of three individual experiments. 
 
 
 
Synthetic peptides reduce pancreatic cancer 
cellular invasion 
It is well known that MMP-2 is involved in can-
cer cellular invasion. In order to confirm the inhibiting 
effects of synthetic peptide M204C4 and M205C4 on 
cancer  cellular  invasion,  the  pancreatic  cancer  cell 
lines PANC-1and CFPAC-1 were applied for this as-
say.  To  observe  the  invasion,  the  pancreatic  cancer 
cells were treated with PGE2 to promote the expres-
sion and activation of MMP-2 (22-23). As document-
ed,  PGE2  increased  MMP-2  extracellular  expression 
but not MMP-9 (Fig.3A) and pancreatic cancer cells 
invasion significantly compared with control subjects 
(Fig.3B). To examine the effect of peptides on the in-
vasion of pancreatic cancer cell lines, matrigel inva-
sion  assays  were  conducted  in  the  presence  of 
M204C4  or  M205C4.  As  shown  in  Fig.4B,  the 
PGE2-stimulated pancreatic cancer cells invaded the 
bottom of the wells as detected by 0.1% crystal violet 
solution  staining.  And  PGE2-mediated  invasion 
through Matrigel was inhibited by synthetic peptides 
in a dose-dependent manner, respectively (Fig.3B and 
3C). These results suggest that M204C4 and M205C4 
have the inhibitory effects on pancreatic cancer cellu-
lar invasion through Matrigel. 
Synthetic peptides attenuate the rate of tumor 
growth in vivo 
Human  xenograft  tumor  model  in  nude  mice 
was utilized for efficacy studies (24). Treatments were 
initiated  when  the  size  of  the  tumor  was  approxi-
mately 0.05 cm3. During the treatment with peptides, 
the growth of tumors originating from human pan-
creatic  cancer  cell  lines  PANC-1  and  CFPAC-1  was 
inhibited (Fig.4). As shown in Fig.4B, tumors (weight) 
inhibitive  rate  of  M205C4  rose  to  more  than  50%, 
compared to controls. Therefore, the therapeutic effect 
of M205C4 was stronger than that of M204C4 at the 
same dose, and the failure of solid tumor formation 
from PANC-1 cells in nude mice treated with M205C4 
was  also  observed  (Fig.4A).  Recent  studies  have 
shown that gelatinases also play a role in the angio-
genesis  and  affect  the  formation  of  the  new  blood 
vessels  nurturing  the  tumor  (25-26).  To  evaluate 
whether the suppression of tumor growth is associ-
ated with angiogenesis, we examined the expression 
of endothelial marker CD31, MMP-2 and Proliferating 
Cell Nuclear Antigen (PCNA) in PANC-1 tumors by 
immunostaining  (Fig.5A).  Microvascular  density 
(MVD) was determined by counting the number of 
the microvessels per high-power field (hpf) in section 
with an antibody reactive to CD31 (Fig.5B). The mean 
MVD that had a significant positive correlation with 
tumor  size  was  reduced  in  tumors  by  peptides.  A 
marked  decrease  of  PCNA-positive  cells  was  ob-
served in the groups treated with peptides (Fig.5C). It 
indicated that two synthetic peptides could suppress 
the proliferation of tumor cells.In addition; it was no-
table that no significant difference in MMP-2 expres-
sion was found  in three groups (Fig.5A). And after Int. J. Biol. Sci. 2012, 8 
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incubation with peptides in vitro for 48h in PANC-1 
and CFPAC-1 cell lines, M204C4 and M205C4 did not 
reduce  MMP-2  mRNA  and  protein  levels  (data  not 
shown). The results suggested that two peptides pos-
sibly  reduced  tumors  proliferation  by  inhibiting 
MMP-2 activation to prevent the angiogenesis of tu-
mors. 
 
 
Fig.3 Effects of M204C4 and M205C4 on cellular invasion in the pancreatic cancer cell lines. After incubation with PGE2 for 
24h without peptides, MMP-2 activity in media was examined by gelatin zymography (A). In transwell assays, cells were treated with 
indicated concentrations of peptides and PGE2 (5μM) for 48h. Representative pictures in all groups (B). Spectrophotometric quantification 
of transwell assays (C), stained cells were dissolved in 10% acetic acid, and the absorbance was read on a spectrophotometer set at 
590 nm. The values are expressed as percentage relative to the untreated control (PEG2).Values are the means±SD (n=3) of three indi-
vidual experiments. *p<0.05, **p<0.01 vs control (PANC-1 group with PEG2); #p<0.05, ##p<0.01 vs control (CFPAC-1 group with PEG2). Int. J. Biol. Sci. 2012, 8 
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Fig.4 The effect of M204C4 and M205C4 on the growth of human xenograft tumor model in mice. All mice (n=6/group) 
with tumor were injected s.c. with peptides (100µM) or PBS weekly. Macroscopic appearance of solid tumors after ending the treatment 
(A). Tumor weight and inhibition rate (B), W: average tumor weight in each group; R: inhibitive rate of tumor. Tumor growth curve(C). 
Tumor volume = (width2 × length)/2; Inhibitive rate of tumor (%) = (1- average tumor weight in treated group/average tumor weight in 
control) × 100%. Data are mean  SD. 
 
 
Pharmacokinetic Disposition 
A major drawback of the use of peptides as an-
ticancer drugs is their rapid metabolism by peptidase 
in vivo (27-29). To understand their metablism in vi-
vo, the pharmacokinetics of two peptides were priorly 
evaluated  in  mice.  The  results  are  summarized  in 
Fig.6.  After  i.v.  administration,  peptides  in  plasma 
were not detected nearly about ten minutes. And no 
significant difference in the parameters was observed 
between two peptides. For this reason, we suggested 
that M204C4 and M205C4 should be used locally but 
not systematically in the drug administration. 
 Int. J. Biol. Sci. 2012, 8 
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Fig.5 Immunohistochemical analysis in cancer tissues. PANC-1 tumors were analyzed by hematoxylin-eosin staining and im-
munohistochemical staining for the expression of MMP-2, CD31 and PCNA (A). Microvessel density of the tumor tissues was assessed by 
CD31 immunohistochemical analysis(B). Anti-PCNA staining in tumor sections from each group, the percentage of PCNA-positive cells 
per 200× field was accounted for as described in the methods(C). Data are mean  SD. *p<0.05, vs control (PBS). Int. J. Biol. Sci. 2012, 8 
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Fig.6 Metabolic stabilities in vivo: Plasma pharmacokinetics of peptides (20mg/kg) i.v. in ICR mice (n=6). Reversed-phase UPLC 
separation of peptides with total ion current (TIC) chromatogram of samples extracted from the supernatant of protein precipitated mice 
plasma, M204C4(A) and M205C4(B). The concentration-time profile for the UPLC-MS analysis of two peptides in vivo(C). Data are mean 
 SD. 
 
DISCUSSION 
Pancreatic  cancer  is  the  fourth  most  common 
cause  of  cancer  death  in  the  world.  For  all  stages 
combined, the 1- and 5-year relative survival rates are 
25% and 6%, respectively. Clinical drugs did not show 
strong therapeutic efficacy combined with a lack of 
side  effects.And  according  to  the  American  Cancer 
Society, there are no established guidelines to prevent 
pancreatic cancer. 
MMP-2 (gelatinase A), which is able to degrade 
type IV collagen, is considered to be especially im-
portant in the degradation of the extracellular matrix 
that is associated with the malignant behavior of tu-
mor cells (30-31). There are no exceptions in pancre-
atic cancer, MMP-2 shows high levels of expression 
and positively associates with tumor progression in 
clinical  and  experimental  models  (32).  Therefore, 
MMP-2 has been considered as a potential therapeutic 
target for pancreatic cancer and other aggressive ma-Int. J. Biol. Sci. 2012, 8 
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lignant  tumors.  Since  small  molecules  with 
non-specific inhibition present inevitable side effects 
in patients, researchers have focused on biochemical 
drugs. Bevacizumab (Avastin) working as a human-
ized monoclonal antibody, which prevented the for-
mation of new blood vessels by targeting and inhib-
iting the function of VEGF, was approved by the U.S. 
Food and Drug Administration (FDA) for cancers in 
2004 (33). And Avastin, as a positive control of angi-
ogenesis, was applied for our experiments in vivo (see 
supplement).  Although  MMP-2  inhibitors  are  not 
used for clinical application, many studies about bio-
logical inhibitors of MMPs have been reported (34-36). 
Phage display is a powerful method to screen in 
vitro random libraries of peptides and to select short 
sequences with high affinity and specificity for bio-
logical  targets.  Using  this  technique  Koivunen  et  al 
(37)  obtained  several  cyclic  peptides  containing  the 
amino acids sequence histidine-tryptophane–glycine- 
phenylalanine  (HWGF)  as  selective  inhibitors  of 
MMP-2  and  MMP-9.  In  our  study,  two  consecutive 
biopanning of a 12-mer peptide phage display library 
against  MMP-2  immobilized  on  Nunc  ELISA  wells 
resulted in identification of 22 different phage clones 
capable of binding to immobilized MMP-2. All these 
clones can inhibit the MMP-2 enzyme activities at the 
same titer with different potency (Fig.1). Chemically 
synthetic peptides M201 to M219 were tested for their 
ability to inhibit MMP-2 activity. Unfortunately, the 
inhibiting effects were very mild (data not shown). In 
order  to  conserve  their  construction  as  the  original 
shape  on  the  surface  of  phage,  the  amino  acid  se-
quence GGGS was added to the C-terminal end of 19 
peptides according to the  protocol  suggestions (38), 
and  M204C4  and  M205C4  showed  higher  binding 
potencies to recombinant human MMP-2 enzyme and 
markedly  inhibited  the  activity  of  recombinant  hu-
man  MMP-2  enzyme  in  vitro  compared  with  other 
peptides. To measure cell invasion assay, Prostaglan-
din E2 (PGE2) promoted cellular invasive potential by 
inducing  matrix  metalloproteinase-2  expression  and 
activity, and PGE2 -mediated invasion was reversed to 
different  extents  by  M204C4  and  M205C4  (Fig.3C). 
Moreover, M209C4 and M214C4 that were randomly 
chosen for invasion assay had no effect on inhibition 
of cellular invasion (data not shown). For these rea-
sons,  it  suggested  that  selected  peptides  might  be 
used as MMP-2 specific inhibitors for the following 
studies. 
As reported, rapid degradation of peptides limits 
its application in the clinic, and these two peptides 
had such problems (Fig.6) and were not used system-
atically. In order to obtain high local concentration, 
we  injected  two  peptides  directly  into  tumor  base-
ment, which  was  prone  to  deliver  peptides directly 
into tumors to be available against the growth of tu-
mors  in  vivo.  And  peptides  were  put  into  diluted 
Matrigel  without  mixing  with  culture  medium  for 
invasion  assay.  These  processes  were  effective  to 
avoid rapid degradation of peptides.The expression of 
matrix metalloproteinase-2 (MMP-2) has been linked 
to  tumor  invasion,  angiogenesis,  and  metastasis. 
(39-40).  Angiogenesis  is  required  for  tumor  growth 
and metastasis and constitutes an important point in 
the  control  of  cancer  progression  (41-42).  The  rela-
tionship of MMP-2 expression and angiogenesis has 
been previously reported and its biological and ther-
apeutic implications remained the focus of investiga-
tions (43-44). MMP-2 might facilitate endothelial cell 
invasion  by  removing  matrix  barriers  or  initiating 
signaling  pathways  that  promote  or  cooperate  the 
angiogenic phenotype (45), so that tumor cells could 
get enough oxygen and other essential nutrients. 
 In  our  studies,  two  peptides  inhibited  the 
growth of tumors from human pancreatic cancer cell 
lines  effectively.  MVD  of  the  tumor  exposed  to  the 
peptides was reduced in a dose dependent manner, 
especially  in  the  high  dose  group.  Meanwhile, 
PCNA-positive  cells  were  decreased  in  treated 
groups, and such change resulted from deficient sup-
plies  for  tumor  growth.  And  no  metastic  colonies 
were found at tissues sections in all groups. It sug-
gested that M204C4 and M205C4 might reduce tumor 
growth  by  inhibition  of  tumor  angiogenesis.  And 
similar to the results in vitro, M205C4 had a stronger 
inhibitory effect on the tumor than M204C4. In fact, 
we have synthesized C-to-N terminally cyclized pep-
tides (c-M204C4 and c-M205C4), Backbone cyclization 
can help to stabilize peptides against degradation, but 
the ability of inhibition to MMP-2 was declined ob-
viously  in  MMP-2  Fluorescent  Assay,  with  IC50  of 
1495.3 nM and 2309.7nM. And cyclized peptides had 
on  significant  effect  on  the  growth  of  tumors  from 
PANC-1  cell  line  (See  supplement).  Therefore,  the 
effect of peptides  on tumor growth was potentially 
associated  with  inhibition  of  MMPs-mediated  tu-
morigenesis  and  metastasis.  The  hypotheses were 
supported by the results that peptides did not induce 
the  apoptosis  and  cycle  arrest  of  pancreatic  cancer 
cells in vitro (data not shown). 
A key consideration in the design of antimeta-
static therapeutic agents is the fact that the decreased 
significant  numbers  of  disseminated  tumor  cells 
should been observed in patient’s blood, bone mar-
row, and distant organ sites upon initial presentation 
in the oncology clinic. However, it was hard to exactly 
estimate the unitary effect of peptides on tumor me-
tastasis with some drawbacks, such as rapid degrada-Int. J. Biol. Sci. 2012, 8 
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tion of peptides and animal model of tumor metasta-
sis. In order to investigate the anti-metastatic efficacy 
of new therapeutic agents, orthotopic models of pan-
creatic cancer had been constructed in nude mice (39, 
46). After improving the pharmacokinetic profile by 
constitutional modification to raise retention time in 
mice, it will be able to evaluate the therapeutic effects 
of peptides in vivo for further studies.  
In conclusion, this study describes the discovery 
of  new  peptides,  M204C4  and  M205C4, which  are 
effective inhibitors of MMP-2. These molecules may 
have future utility in clinical applications for treating 
cancer  and  other  diseases  associated  with  MMP-2 
up-regulation. 
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